Pharmacotherapy for post-traumatic stress disorder: a comprehensive review.
Pharmacotherapy for post-traumatic stress disorder: a comprehensive review.
复制标题
DOI：
10.1517/14656566.2.10.1583
复制
发表时间：
2001-10-01
影响因子：
3.2
通讯作者：
Petty, F
中科院分区：
文献类型：
--
作者：
Davis, L L;English, B A;Petty, F
在过去的五年中，在确定创伤后应激障碍（PTSD）的有效治疗方法方面取得了重大进展。目前，舍曲林是fda批准的第一个也是唯一一个治疗这种复杂且经常是慢性疾病的药物。其他5 -羟色胺类抗抑郁药，如帕罗西汀、氟西汀和奈法唑酮，都有良好的对照或可重复的公开标签疗效证据。抗惊厥药也被研究作为治疗的潜在替代品。最后，非典型抗精神病药物在开放标签试验中显示出前景。显然，需要更多的对照研究。在男性和战斗创伤性PTSD中尤其如此，药物治疗的效果不如女性或平民创伤性PTSD强。此外，几乎没有关于儿童急性应激反应或创伤后应激障碍的药物治疗的数据。未来的研究方向可能集中在更耐药的患者群体的联合治疗上。
Significant advances have been made in the past 5 years in defining efficacious treatments for post-traumatic stress disorder (PTSD). Currently, sertraline is the first and only FDA-approved medication for this complex and often chronic illness. Other serotonergic antidepressants, such as paroxetine, fluoxetine and nefazodone, have well-controlled or replicated open-label evidence of efficacy. Anticonvulsants are also being studied as potential alternatives to treatment. Finally, atypical antipsychotic medications have shown promise in open-label trials. Clearly, more controlled studies are needed. This is especially true in males and in combat trauma-induced PTSD, where the effects of pharmacotherapy are less robust than in females or civilian trauma-induced PTSD. Also, there are virtually no data on pharmacotherapy for acute stress reaction or for PTSD in children. Future directions for research may focus on combination treatment in the more treatment-resistant patient populations.